Poliovirus vaccination during the endgame: insights from integrated modeling

References

• World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Geneva: World Health Organization; 1988.
   Google Scholar
• Thompson KM, Pallansch MA, Duintjer Tebbens RJ, et al. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33:647–663.
   PubMed Web of Science ®Google Scholar
• World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). Geneva: World Health Organization; 2008.
   Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26:1471–1505.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kim J-H, et al. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;23:680–702.
   Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. How should we prepare for an outbreak of reintroduced live polioviruses? Future Virol. 2017;12:41–44.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Polio this week as of 8 February 2017. [cited 2017 Feb 11]. Available from: http://polioeradication.org/polio-today/polio-now/this-week/.
   Google Scholar
• Kew OM, Cochi SL, Jafari HS, et al. Possible eradication of wild poliovirus type 3 – worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014;63:1031–1033.
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared 2015 [updated September 20, 2015; cited 2015 November 30]. Available from: http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx
   Google Scholar
• Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine – worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934–938.
   PubMed Web of Science ®Google Scholar
• UNICEF. RFP-DAN-2016-502330 Bivalent oral polio vaccines 2017 [cited 2017 January 13]. Available from: https://www.unicef.org/supply/index_94239.html.
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Rev Vaccines. 2012;11:449–459.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis. 2015;15:376.
   PubMed Web of Science ®Google Scholar
• Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine – live. Plotkin SA, Orenstein WA, Offit PA, et al., editors. Vaccines. Sixth ed ed. Philadelphia:Saunders Elsevier; 2013. p.598–645.
   Google Scholar
• Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210:S380–9.
   PubMed Web of Science ®Google Scholar
• Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356–359.
   PubMed Web of Science ®Google Scholar
• Kew O, Sutter R, Nottay B, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 1998;36:2893.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, et al. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccin. 2016;7:340.
   PubMedGoogle Scholar
• World Health Organization. Global polio eradication initiative: polio eradication and endgame strategic plan (2013–2018). Geneva: World Health Organization; 2013. (no. WHO/POLIO/13.02).
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210:S475–S84.
   PubMed Web of Science ®Google Scholar
• Etsano A, Damisa E, Shuaib F, et al. Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission – Nigeria, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:770–773.
   PubMed Web of Science ®Google Scholar
• Vidor E. Plotkin SA. Poliovirus vaccine – inactivated. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Sixth ed ed. Philadelphia: Saunders Elsevier; 2013. p. 573–597.
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Exp Rev Vaccines. 2014;13:221–234.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Pallansch MA, Duintjer Tebbens RJ, et al. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013;33:516–543.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, October 2016 – conclusions and recommendations. Wkly Epidemiol Rec. 2016;91:561–584.
   PubMedGoogle Scholar
• Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012;16:e110–e6. Epub 2011/12/14.
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, Al Awaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351–2359. Epub 2010/06/25
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2011;201:1344–1352. Epub 2010/03/31
   Web of Science ®Google Scholar
• Resik S, Tejeda A, Mach O, et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine. 2015;33:307–313.
   PubMed Web of Science ®Google Scholar
• Anand A, Zaman K, Estivariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine. 2015;33:6816–6822.
   PubMed Web of Science ®Google Scholar
• Fine PEM, Sutter RW, Orenstein WA. Stopping a polio outbreak in the post-eradication era. Dev Biol. 2001;105:129–147.
   Google Scholar
• Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med. 2008;10:190.
   PubMedGoogle Scholar
• Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal. 2006;26:1541–1556.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Alexander JP Jr., et al. Optimal vaccine stockpile design for an eradicated disease: application to polio. Vaccine. 2010;28:4312–4327. Epub April 27.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis. 2015;15:389.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis. 2015;15:390.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples. Risk Anal. 2016;36:1487–1509.
   PubMed Web of Science ®Google Scholar
• Current UNICEF OPV supply & outlook – July 2013.[cited 2017 Feb 14]. Available from: https://www.unicef.org/supply/files/Oral_polio_vaccine_update.pdf.
   Google Scholar
• UNICEF. Oral polio vaccine supply outlook. September 2014.[cited 2017 Feb 14]. Available from: https://www.unicef.org/supply/files/Oral_Polio_Vaccine_Outlook__September_2014.pdf.
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210:S485–S97.
   PubMed Web of Science ®Google Scholar
• UNICEF. Oral polio vaccine supply outlook – December 2015 [cited 2017 Feb 14]. Available from: https://www.unicef.org/supply/files/Oral_Polio_Vaccine_Outlook__December_2015.pdf.
   Google Scholar
• World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations. Wkly Epidemiol Rec. 2015;90:681–700.
   PubMedGoogle Scholar
• UNICEF. Inactivated poliovirus vaccine supply alert – May 2016. [cited 2017 Feb 14]. Available from: https://www.unicef.org/supply/files/Inactivated_Polio_Vaccine_(IPV)_-_may_2015_banner.pdf.
   Google Scholar
• UNICEF. Inactivated poliovirus vaccine: Supply update – September 2016. [cited 2017 Feb 14]. Available from: https://www.unicef.org/supply/files/Inactivated_Polio_Vaccine_(IPV)_-_september_2016.pdf.
   Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. Medical Decision Making Policy & Practice. 2017;2:1–13.
   Google Scholar
• Anis E, Kopel E, Singer S, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 2013;18:pii=20586.
   PubMedGoogle Scholar
• Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211:1800–1812.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205:237–243. Epub 2011/12/14
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Fonseca M, et al. Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies. Trials Vaccinol. 2015;4:71–74.
   PubMedGoogle Scholar
• Simizu B, Abe S, Yamamoto H, et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals. 2006;34:151–154.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential OPV cessation risk management strategy. Epidemiol Infect. 2017;145:217–226.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiol. 2016;11:1549–1561.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23:703–749.
   Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis. DOI:10.1093/infdis/jix128
   Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis. 2016;16:237.
   PubMed Web of Science ®Google Scholar
• Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis. 2016;16:231.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis. 2017. DOI:10.1093/infdis/jix108
   Web of Science ®Google Scholar
• Adeyemi OO, Nicol C, Stonehouse NJ, et al. Increasing type 1 poliovirus capsid stability by thermal selection. J Virol. 2017;91(4):e01586-16. DOI:10.1128/JVI.01586-16
   Web of Science ®Google Scholar
• Macadam AJ, Ferguson G, Stone DM, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol. 2006;80:8653–8663. Epub 2006/08/17
   PubMed Web of Science ®Google Scholar